These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191 [TBL] [Abstract][Full Text] [Related]
3. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193 [TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: a prospective open trial. Tang WK; Ungvari GS Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):373-9. PubMed ID: 12691772 [TBL] [Abstract][Full Text] [Related]
6. Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. Abuzzahab FS; Zimmerman RL J Clin Psychiatry; 1982 Mar; 43(3):105-10. PubMed ID: 7037757 [TBL] [Abstract][Full Text] [Related]
7. Scales for the assessment of neuroleptic response in schizophrenic children: specific measures derived from the CPRS. Spencer EK; Alpert M; Pouget ER Psychopharmacol Bull; 1994; 30(2):199-202. PubMed ID: 7831455 [TBL] [Abstract][Full Text] [Related]
8. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Research Units on Pediatric Psychopharmacology Autism Network Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814 [TBL] [Abstract][Full Text] [Related]
9. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249 [TBL] [Abstract][Full Text] [Related]
10. Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial. Ko YH; Lew YM; Jung SW; Joe SH; Lee CH; Jung HG; Lee MS J Clin Psychopharmacol; 2008 Aug; 28(4):375-83. PubMed ID: 18626263 [TBL] [Abstract][Full Text] [Related]
11. [Comparative efficacy of bromocriptine, carbamazepine and cyproheptadine with neuroleptics in 24 refractory chronic schizophrenic patients]. Llorca PM; Wolf MA; Lançon C; Bougerol T Encephale; 1993; 19(5):565-71. PubMed ID: 8306925 [TBL] [Abstract][Full Text] [Related]
12. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Levin FR; Evans SM; Brooks DJ; Kalbag AS; Garawi F; Nunes EV Drug Alcohol Depend; 2006 Feb; 81(2):137-48. PubMed ID: 16102908 [TBL] [Abstract][Full Text] [Related]
13. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287 [TBL] [Abstract][Full Text] [Related]
15. Acute effects of the synthetic analogue of methionine enkephalin FK 33-824 in schizophrenic patients. A double blind trial. Jungkunz G; Nedopil N; Rüther E Pharmacopsychiatry; 1984 May; 17(3):76-8. PubMed ID: 6739537 [TBL] [Abstract][Full Text] [Related]
16. Methylphenidate challenge as a predictor of relapse in schizophrenia. Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506 [TBL] [Abstract][Full Text] [Related]
17. A preliminary study of the effect of pyridoxine administration in a subgroup of hyperkinetic children: a double-blind crossover comparison with methylphenidate. Coleman M; Steinberg G; Tippett J; Bhagavan HN; Coursin DB; Gross M; Lewis C; DeVeau L Biol Psychiatry; 1979 Oct; 14(5):741-51. PubMed ID: 497303 [TBL] [Abstract][Full Text] [Related]
18. Mood responses of remitted schizophrenics to methylphenidate infusion. Robinson D; Mayerhoff D; Alvir J; Cooper T; Lieberman J Psychopharmacology (Berl); 1991; 105(2):247-52. PubMed ID: 1796130 [TBL] [Abstract][Full Text] [Related]
19. Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent? van Kammen DP; Hommer DW; Malas KL Neuropsychobiology; 1987; 18(3):113-7. PubMed ID: 3453426 [TBL] [Abstract][Full Text] [Related]
20. Pilot study on the effects of fenfluramine on negative symptoms in twelve schizophrenic inpatients. Stahl SM; Uhr SB; Berger PA Biol Psychiatry; 1985 Oct; 20(10):1098-102. PubMed ID: 3899199 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]